A Phase II Study of Docetaxel and Infusional Cisplatin in Advanced Non-Small-Cell Lung Cancer

Mori, Kiyoshi; Kamiyama, Yukari; Kondo, Tetsuro; Kano, Yasuhiko; Kodama, Tetsuro

doi:10.1159/000085619

Cited by 12 publications

(11 citation statements)

References 34 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, preclinical pharmacokinetic studies on docetaxel have shown that its hepatobiliary excretion is the major route of elimination, while renal excretion is minimal (<5%) [18,19,20]. Thus, it seems that docetaxel is a suitable anticancer agent for patients immediately after surgery.…”

Section: Discussionmentioning

confidence: 99%

Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy

et al. 2011

View full text Add to dashboard Cite

Objective: The aim of this prospective study was to evaluate the feasibility and safety of adjuvant S-1 plus docetaxel in patients with stage III gastric cancer. Methods: We enrolled 53 patients with pathological stage III gastric cancer who underwent D2 gastrectomy. They received oral S-1 (80 mg/m²/day) administration for 2 consecutive weeks and intravenous docetaxel (40 mg/m²) on day 1, repeated every 3 weeks (1 cycle). The treatment was started within 45 days after surgery and repeated for 4 cycles, followed by S-1 monotherapy (4 weeks on, 2 weeks off) until 1 year after surgery. The feasibility of the 4 cycles of chemotherapy, followed by S-1 administration, was evaluated. Results: A total of 42 patients (79.2%, 95% CI 65.9–82.9) tolerated the planned 4 cycles of treatment with S-1 and docetaxel, and 34 patients (64.2%, 95% CI 49.8–76.9) completed subsequent S-1 monotherapy for 1 year. Grade 4 neutropenia was observed in 28% and grade 3 febrile neutropenia in 9% of the patients, while grade 3 nonhematological toxicities were relatively low. Conclusions: Adjuvant S-1 plus docetaxel therapy is feasible and has only moderate toxicity in stage III gastric cancer patients. We believe that this regimen will be a candidate for future phase III trials seeking the optimal adjuvant chemotherapy for stage III gastric cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In recent years, various new promising agents were introduced to treat non-small cell lung cancer (NSCLC) [2,3,4,5], and the use of these agents in combination chemotherapy with CDDP was found to be the most effective [6,7,8]. Currently, platinum agents combined with new-generation anti-tumor agents are considered to be the standard for chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

Mori¹,

Kamiyama²,

Kasai³

et al. 2012

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). Methods: 46 chemotherapy-naive patients with measurable NSCLC were enrolled. Patients underwent a combination chemotherapy of GEM 1,000 mg/m2 plus CBDCA at an area under the curve of 2 on days 1 and 8 every 3 weeks. Results: Response rate was 30% (14/46; 95% confidence interval: 17.7–45.8%). The median number of treatment cycles was 3 (range 1–2). Time to progressive disease was 19.4 weeks and the median survival was 46.3 weeks. The 1-year survival rate was 46.9%. The major toxicity was hematotoxicity: grade 3 or 4 neutropenia (58.7%) and thrombocytopenia (45.7%). There were no other severe toxicities. Conclusion: Weekly chemotherapy with CBDCA plus GEM is a well-tolerated and promising regimen as first-line treatment of advanced NSCLC.

show abstract

“…Despite many aggressive approaches to therapy and new chemotherapeutic agents [2] , survival rates have only slightly changed in the last decade. Non-small cell lung cancers (NSCLC), including adenocarcinomas, constitute the majority of lung cancers (75-80%).…”

Section: Introductionmentioning

confidence: 99%

Clarithromycin Suppresses Invasiveness of Human Lung Adenocarcinoma Cells

Wada

Sata²,

Sato³

et al. 2007

Chemotherapy

View full text Add to dashboard Cite

Background: It has been speculated that clarithromycin (CAM), a 14-membered ring macrolide, possesses antitumor effects besides antimicrobial and anti-inflammatory effects. Method: We evaluated the effects of CAM on the growth and invasiveness of A549 lung adenocarcinoma cells. Results: Although CAM did not affect the growth of A549 cells, the Matrigel invasion assay showed that the potential of invasion was diminished by CAM treatment. When analyzed by flow cytometry, CAM suppressed α₂- and β₁-integrin expression. Furthermore, thymidine phosphorylase (TP) expression was diminished by CAM treatment in a dose-dependent manner. A specific TP inhibitor also suppressed β₁-integrin expression in flow cytometric analysis. Conclusions: These results suggest that CAM may suppress invasive activity of A549 cells in part by diminishing the expression of TP, α₂- and β₁-integrin, which may be a downstream signal of the TP pathway, and that CAM could be useful in the treatment of lung adenocarcinoma.

show abstract

A Phase II Study of Docetaxel and Infusional Cisplatin in Advanced Non-Small-Cell Lung Cancer

Cited by 12 publications

References 34 publications

Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy

Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

Clarithromycin Suppresses Invasiveness of Human Lung Adenocarcinoma Cells

Contact Info

Product

Resources

About